Plasmodium falciparum and Plasmodium vivax, the two protozoan parasite species that
cause the majority of cases of human malaria, have developed resistance to nearly all …

This article outlines genome-scale approaches that can be used to identify mutations in
malaria (Plasmodium) parasites that underlie drug resistance and contribute to treatment …

Plasmodium vivax is the most geographically widespread cause of human malaria and is
responsible for the majority of cases outside of the African continent. While great progress …

Multidrug-resistant Plasmodium falciparum malaria parasites pose a threat to effective drug
control, even to artemisinin-based combination therapies (ACTs). Here we used linkage …

Chemogenetic characterization through in vitro evolution combined with whole-genome
analysis can identify antimalarial drug targets and drug-resistance genes. We performed a …

Malaria is a major public health burden throughout the world. Resistance to the antimalarial
drugs has increased the mortality and morbidity rate that is achieved so far through the …

Despite intensive research extending back to the 1930s, when the first synthetic antimalarial
drugs made their appearance, the repertoire of clinically licensed formulations remains very …

Highlights•The antimalarial pipeline has been enriched with new molecules and
targets.•The antimalarial target compound and product profiles have been redefined.•In …

Drug resistance in malaria parasites is a serious public health burden, and resistance to
most of the antimalarial drugs currently in use has been reported. A better understanding of …

The number of available and effective antimalarial drugs is quickly dwindling. This is mainly
because a number of drug resistance-associated mutations in malaria parasite genes, such …